Dr Neeraj Agarwal on Why PARP Inhibitor Approval in Prostate Cancer Is Slow-Moving
FDA approvals for PARP inhibitors in prostate cancer treatment have taken longer than in ovarian cancer treatment. Neeraj Agarwal, MD, a... Read More
Improving Risk Stratification Among Veterans Diagnosed With Prostate Cancer: Impact of the 17-Gene Genomic Prostate Score Assay
Active surveillance (AS) has been widely implemented within Veterans Affairs’ medical centers (VAMCs) as a standard of care for low-risk... Read More
PCORI-Funded Study Advises Patient Preference When Treating Prostate Cancer
Comparing the immediate and long-term impact of radical prostatectomy, external beam radiotherapy, brachytherapy, and active surveillance, a study published in... Read More